Navigation Links
Bacteria ferry nanoparticles into cells for early diagnosis, treatment

at are drawn into the cell's interior. Once inside the cell, the bacteria dissolve the vesicle membrane and release the cargo.

The method might be used to take images of diseased tissues by inserting a cargo of fluorescent molecules into tumors that are ordinarily too small to be detected, said Demir Akin, a research assistant professor of biomedical engineering who specializes in nanomedicine.

"These bacteria can potentially deliver specific molecules into a variety of cells," said Akin, the first author of a research paper appearing online this week in the journal Nature Nanotechnology.

Experiments were carried out in cultures of human cancer cells, including intestinal, oral, liver, ovarian and breast cancer cells. The researchers also tested their method on live mice and showed how the technique could be used to deliver specific genes to various organs, including the liver and kidneys.

"The cells in the organs receiving the bacteria with nanoparticles made the intended therapeutic proteins and emitted a light similar to a firefly's glow," Akin said.

Certain bacteria are naturally programmed to dissolve vesicle membranes, a critical step to delivering the cargo. The nanoparticles are referred to as "smart" because they release their cargo at precisely the right moment after entering the cell.

"At the same time that the bacteria are breaking up this vesicle membrane, the cargo dislodges from the bacteria, which are both crucial steps in delivering this cargo," Akin said.

The nanoparticles, which range in size from 40 to 200 nanometers - or billionths of a meter - are attached to the bacteria with "linker molecules."

"The use of commercially available polystyrene nanoparticles makes this delivery system much simpler to implement than previous alternatives," Bashir said.

This new delivery system also is more efficient than other experimental techniques using viruses and bacteri
'"/>

Source:Purdue University


Page: 1 2 3

Related biology news :

1. Bacteria collection sheds light on urinary tract infections
2. Solution to Pollution: New Bacteria Eats Toxic Waste
3. The Bacterias guide to survival
4. UF Researchers Map Bacterial Proteins That Cause Tooth Loss
5. Bacterial genome sheds light on synthesizing cancer-fighting compounds
6. Where Bacteria Get Their Genes
7. Bacteria feed on smelly breath (and feet)
8. New insight into autoimmune disease: Bacterial infections promote recognition of self-glycolipids
9. Bacteria use hosts immune response to their competitive advantage
10. Say what? Bacterial conversation stoppers
11. Bacteria are key to green plastics, drugs
Post Your Comments:
(Date:8/11/2015)... August 11, 2015 Today, ZUK announced its ... as well as expected revenues in 2015 that relate to sales ... revenue guidance of approximately 2,200 MSEK for 2015. Jörgen ... prominent smartphone manufacturer in China ... selected FPC1 155 for Z1 ...
(Date:8/6/2015)... , Aug. 6, 2015 Synaptics ... of human interface solutions, today announced collaboration with ... on Windows 10. Microsoft leveraged Synaptics, deep expertise ... operating system. Through stringent testing, ... fully certified with Microsoft,s Precision TouchPad (PTP) specification ...
(Date:8/4/2015)... AMRI ) today reported financial and operating results for the ... Second quarter contract revenue of $ 85.2 ... contract margins of 26 % , Second ... EPS from royalties in the current quarter , ... very pleased to present another strong financial quarter, with all our ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
... PHILADELPHIA (July 30, 2012) When the longest cells in the ... repair is no easy task. This is in part because ... to one meter in adult humans which is a ... in order to reach the "command center" of the cell,s ...
... 2012) -- A rat may never be man,s best ... sponsored by scientists with the U.S. Army Research Laboratory, ... Counter Explosives Hazards Center, will determine if and how ... In July, Barron Associates Inc., Charlottesville, Va. was ...
... Xian Chang Li, MD, PhD, Brigham and Women,s Hospital (BWH) ... of lymphocytes, called CD4+ T cells, mature into various subsets ... that a particular cell surface molecule, known as OX40, is ... copious amounts of interleukin-9 (IL-9) (and therefore called TH9 cells) ...
Cached Biology News:Long-distance distress signal from periphery of injured nerve cells begins with locally made protein 2Long-distance distress signal from periphery of injured nerve cells begins with locally made protein 3RATS research may teach rodents to detect explosives 2Cell receptor has proclivity for T helper 9 cells, airway inflammation 2
(Date:8/26/2015)... , August 26, 2015 Israel Proves ... DiaCardio wins 1 st place  Wayerz comes in ... Israel by venture capital fund JVP, with ... the US, China , Israel ... .  Impressive achievement for the Israeli representatives in ...
(Date:8/26/2015)... Boston, MA (PRWEB) , ... August 26, 2015 , ... ... venue for Boston adult stem cell technology start-up company Asymmetrex to share ... widely the capabilities of a new biomarker for counting adult tissue stem cells. , ...
(Date:8/25/2015)... Calif. (PRWEB) , ... August 25, 2015 , ... One ... Valley -based Resilinc Corp., Bindiya Vakil, has been on a mission for ... the impact on global supply chain operations - from the two massive explosions that ...
(Date:8/25/2015)... PRUSSIA, Pa. , Aug. 25, 2015   ... has been enrolled in its Phase II/III clinical study ... company,s recombinant fusion protein linking coagulation factor VIIa with ... hemophilia A or B who have developed an inhibitor ... study will enroll approximately 54 male patients, the first ...
Breaking Biology Technology:Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 4Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 2Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 3Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 4CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors 2CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors 3CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors 4
... Cardium Therapeutics,(NYSE: CXM ) today reported ... of Medicine showing the long-term outcome of a method ... disorder of the immune system.,The infant children studied had ... arises in infants with a genetic defect that,leaves them ...
... Shares of Common StockAt a Price of $5.00 per ... Group, Inc. (the "Company" or "PharmaNet") (Nasdaq: ... today announced that it has signed a definitive merger ... ("JLL"). Under the terms of the Merger Agreement, JLL ...
... Secondary Endpoints -- CAPACITY 1 Misses Primary Endpoint, Provides ... MAA -BRISBANE, Calif., Feb. 3 InterMune, Inc. (Nasdaq: ... two Phase 3 CAPACITY studies evaluating pirfenidone in patients ... of change in percent predicted Forced Vital Capacity (FVC) ...
Cached Biology Technology:Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine 2Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine 3Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine 4Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine 5PharmaNet Development Group Agrees to be Acquired by JLL Partners 2PharmaNet Development Group Agrees to be Acquired by JLL Partners 3PharmaNet Development Group Agrees to be Acquired by JLL Partners 4PharmaNet Development Group Agrees to be Acquired by JLL Partners 5PharmaNet Development Group Agrees to be Acquired by JLL Partners 6PharmaNet Development Group Agrees to be Acquired by JLL Partners 7InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 2InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 3InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 4InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 5InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 6InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 7InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 8InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 9InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 10InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 11
... the template-directed polymerization of nucleotides into duplex ... I possesses a 3?5 exonuclease activity or ... during DNA replication, and also contains a ... to replace nucleotides in the growing strand ...
Request Info...
supplied with 10x reaction buffer...
... ATP: D-hexose 6- phosphotransferase/D-glucose-6-phosphate: NADP ... of HK will phosphorylate 1 ... min at 25C at pH ... will oxidize 1 mol of ...
Biology Products: